Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03201952 · ClinicalTrials.gov registry record · Phase 1
Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03201952 is a Phase 1 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT03201952, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This project will evaluate distal intestinal bile salt administration in humans by deliving ursodeoxycholic acid (UDCA) into the terminal ileum of subjects with a pre-existing ileostomy and assessing several hormone levels following an oral glucose tolerance test compared to a placebo.
Interventions
- DRUG Placebos
- DRUG Ursodeoxycholic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2020-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03201952
The ClinicalTrials.gov registry entry for NCT03201952 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03201952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03201952 about?
NCT03201952 is a clinical study titled "Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans". This project will evaluate distal intestinal bile salt administration in humans by deliving ursodeoxycholic acid (UDCA) into the terminal ileum of subjects with a pre-existing ileostomy and assessing several hormone levels following an oral glucose tolerance test compared to a placebo.
What is the current status of trial NCT03201952?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2018-02-01. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT03201952?
The interventions under investigation include: Placebos (DRUG), Ursodeoxycholic Acid (DRUG).
Who is sponsoring clinical trial NCT03201952?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.